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Abstract: Cardiovascular magnetic resonance (CMR) imaging has evolved rapidly and is now accepted as a powerful 
diagnostic tool with significant clinical and research applications. Clinical 3 Tesla (3 T) scanners are increasingly 
available and offer improved diagnostic capabilities compared to 1.5 T scanners for perfusion, viability, and coronary 
imaging. Although technical challenges remain for cardiac imaging at higher field strengths such as balanced steady state 
free precession (bSSFP) cine imaging, the majority of cardiac applications are feasible at 3 T with comparable or superior 
image quality to that of 1.5 T. This review will focus on the benefits and limitations of 3 T CMR for common clinical 
applications and examine areas in development for potential clinical use. 
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INTRODUCTION 
  Cardiovascular magnetic resonance (CMR) has become a 
widely adapted imaging modality for the diagnosis of cardio-
vascular disease, and its clinical indications have expanded 
greatly in the last decade [1]. Recently, 3 T CMR has 
become available and has demonstrated advantages over 1.5 
Tesla over a broad range of clinical applications, for example 
perfusion imaging [2-5]; delayed enhancement [6, 7]; 
myocardial tagging [8, 9]; and coronary magnetic resonance 
imaging [10]. This review will focus on the recent advances 
and clinical utility of 3 T CMR and the potential limitations 
of the technique.  
CARDIAC FUNCTION 
  For cardiac cine imaging, balanced steady-state free 
precession (bSSFP) techniques are employed at 1.5 T and are 
considered the gold standard for evaluating cardiac function 
[11]. The application of accelerated parallel imaging tech-
niques employing multiple receive coils show that bSSFP 
cine imaging at 3 T is at least comparable to that of 1.5 T 
[12, 13]. However, at higher magnetic field strengths, there 
are technical challenges associated with cardiac bSSFP 
imaging because of increased inhomogeneities of the static 
magnetic field (B0) [14]. High signal-to-noise ratio (SNR) 
and contrast-to-noise ratio (CNR) between blood and cardiac 
muscle in bSSFP imaging comes at the cost of so called 
“dark band” artifacts. These artifacts appear further away 
from the determined imaging frequency when a shorter ima-
ging repetition time (TR) is employed [15]. They degrade 
overall image quality [16] and one group observed off- 
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resonance artifacts in 86% of subjects [6]. There are two 
steps to be taken to minimize dark band artifacts [17]: First, 
the TR needs to be chosen as short as possible to push the 
bands away from the heart. Short TRs, however, are 
challenged by the increased energy deposition at 3 T com-
pared to 1.5 T and the desire for high excitation angles and 
long readouts to increase contrast and resolution, respec-
tively. Second, B0 field homogeneity should be optimized 
over the heart with localized second order shimming and 
correct determination of the imaging frequency [17-19]. 
Although bSSFP cine imaging at 3 T is feasible (Fig. 1), 
currently implemented shim routines do not completely shift 
dark band artifacts from cardiac structures in all cases [13].  
  Spoiled gradient echo (GRE) techniques are applied at 3 
T for cine imaging and have shown superior results in 
comparison to 1.5 T [20, 21]. A major disadvantage of GRE 
techniques for cine imaging is the relative dependence on 
inflow for contrast between the myocardium and blood, 
which may lead to reduced contrast particularly in the long 
axis views. Therefore, if the blood flow is depressed such as 
in severe left ventricular (LV) dysfunction, the blood 
becomes saturated, resulting in lower contrast between the 
chamber and ventricular wall. In GRE techniques both 
extravascular and intravascular contrast agents have been 
employed to improve endocardial border definition for the 
accurate quantification of wall motion [22, 23]. A practical 
approach is to perform LV function imaging shortly after 
contrast administration with gadolinium and before obtaining 
delayed enhancement images [23]. 
TAGGING 
  Myocardial tagging has been increasingly employed for 
the accurate, semi-automated analysis of myocardial wall 
motion and strain measurement [24]. The technique is used 
to track the deformation of a presaturation line or grid   238 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Hays et al. 
throughout the cardiac cycle. When combined with cine 
imaging, myocardial tagging provides a quantitative estima-
tion of regional wall motion abnormalities, particularly when 
combined with strain-encoded techniques or harmonic phase 
methods [25]. One of the limitations of tagging is that tag 
lines fade during end-diastole. Several studies have shown 
that myocardial tagging techniques are improved at 3 T 
compared to 1.5 T due to higher SNR, CNR and reduced 
fading of tags in diastole because of the increased T1 at 
higher field strengths [8, 9, 26]. Newer advances such as the 
use of real time fast strain-encoded MRI (fast-SENC) has 
been employed to acquire images in a single heartbeat 
without the need for breath hold techniques, which is 
valuable for the study of patients. Fast-SENC was shown to 
be superior to conventional tagging techniques for the 
assessment of regional myocardial function at 3 T [27]. In 
addition, strain-encoding techniques at 3 T may be useful for 
the evaluation of right-ventricular regional function [28], 
which has traditionally been challenging.  
CMR PERFUSION 
  Myocardial perfusion magnetic resonance (MR) imaging 
has evolved considerably over the past decade and is used to 
assess the significance of coronary artery stenosis and micro-
vascular dysfunction on the myocardium. Clinical studies 
performed with 1.5 T scanners have shown that MR 
perfusion imaging yields superior diagnostic results for the 
detection of CAD to clinically established nuclear perfusion 
techniques [29-31]. By capturing the first pass of a contrast 
agent using an inversion-recovery gradient echo technique or 
equivalent, high temporal resolution images can be generated 
that provide a valuable diagnostic tool particularly for the 
evaluation of intermediate risk patients with chest pain [1]. 
However, because perfusion imaging requires a fast 
acquisition time, it is performed with relatively low spatial 
resolution at 1.5 T which may cause dark rim artifacts that 
may be mistaken for areas of hypoperfusion. Perfusion 
imaging benefits from the high SNR achievable at 3 T (Fig. 
2) and may reduce the occurrence of dark ring artifacts. 
Significant improvements in SNR and overall image quality 
have been reported for perfusion imaging at 3 T [3, 26, 32]. 
One study showed that the diagnostic accuracy of 3 T 
perfusion imaging with adenosine is superior to that of 1.5 T 
(90% vs. 82%) when identifying patients with significant 
coronary artery stenoses [33]. A recent report demonstrated 
that the abundant spatiotemporal correlation enables highly 
accelerated perfusion MR imaging with high spatial 
resolution at 3 T and improves SNR and image quality 
compared with those at 1.5 T. Compared with perfusion MR 
imaging at lower spatial resolution, image quality was 
improved and artifacts were reduced [34].  
DOBUTAMINE CMR 
  Dobutamine stress CMR has become a well established 
modality for the diagnosis of myocardial ischemia. It has 
improved sensitivity and specificity for the detection of 
myocardial ischemia when compared with other stress 
techniques such as dobutamine stress echocardiography and 
is beneficial in patients with poor acoustic windows for 
echocardiography [35]. Dobutamine CMR has a powerful 
prognostic value for patients with suspected or known CAD 
and it has a high negative predictive value for future 
cardiovascular events [36]. A recent study examined the 
feasibility and accuracy of stress imaging at 3 T using high 
dose dobutamine. In patients with suspected or known 
coronary artery disease (CAD), resting cine images using a 
spoiled gradient echo technique were performed immediately 
after the administration of gadolinium to improve image 
quality. This study reported a sensitivity and specificity of 
80.0% and 85.7%, respectively, for the detection of 
Fig. (1). Balanced steady-state free precession (bSSFP) ventricular function images acquired with a 32 channel receiver coil at 3T. (A) 4-
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significant flow-limiting coronary stenosis as defined on 
cardiac catheterization [37]. The implementation of parallel 
imaging will likely further enhance the temporal and spatial 
resolution, as well as accuracy of stress protocols in the 
future.  
LATE GADOLINIUM ENHANCEMENT 
  The measurement of late gadolinium enhancement (LGE) 
of the myocardium using gadolinium has been broadly 
accepted in recent years as the imaging method of choice to 
evaluate myocardial scar [38]. The technique of LGE has 
been validated as a means to assess the amount of nonviable 
myocardium as a percentage of the transmural extent in a 
given segment and is inversely related to the likelihood of 
functional recovery after revascularization [39]. The degree 
and extent of myocardial scar as measured by MRI has a 
strong predictive value for future cardiovascular events [40]. 
The higher achievable SNR at 3 T may benefit cardiac scar 
imaging by providing higher contrast between healthy and 
diseased (non-viable) myocardium. In patients with a history 
of myocardial infarction, a higher image quality of LGE was 
demonstrated at 3 T compared to 1.5 T [6]. Another group 
performed intra-subject comparisons in patients with a 
history of acute and chronic myocardial infarction using the 
same contrast-enhanced viability protocol at both 1.5 and 3 
T, and found very close agreement for myocardial 
enhancement [7].  
  There are several recent studies that examine potential 
benefits of 3 T imaging in LGE (Fig. 3). One advantage is 
the possibility of reducing the dose of contrast agent at 3 T 
Fig. (2). Patient with stress-inducible anterior and anteroseptal perfusion defect (black arrows). Scans show A, apical and B, equatorial short-
axis views during stress; C and D show perfusion images at rest. E, Coronary angiography shows 90% stenosis (white arrow) of proximal 
LAD. With permission of [2]. 
Fig. (3). Late gadolinium enhancement images of a patient with chronic myocardial infarction of the septal ventricular wall, including the
apex (white arrows). Images in basal short-axis view (A) and 4-chamber view (B) at 3 T acquired 15 minutes after injection of 0.15 mmol 
gadolinium/kg body weight. 240 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Hays et al. 
[41]. In addition, the higher spatial resolution may help to 
better delineate infarct zones from peri-infarct regions, 
which may be a focus of ventricular arrythmias and has been 
reported to be a strong predictor of future cardiovascular 
events [42]. Recently, newer methods such as stimulated-
echo acquisition mode (STEAM) MRI have been imple-
mented at 3 T for black-blood LGE myocardial imaging 
[43]. This method demonstrates good agreement with 
standard inversion recovery LGE imaging and allows for 
improved determination of the blood-infarct border which 
may enhance the measurement of infarct size.  
CORONARY MRI 
  Coronary magnetic resonance angiography (MRA) 
provides a non-invasive, safe means to evaluate the coronary 
arteries, and may be improved at 3 T [44]. An initial study of 
coronary angiography at 3 T in healthy adults reported a 
higher spatial resolution compared to that achievable at 1.5 T 
[10]. One group reported an intraindividual comparison of 
3D bSSFP coronary MRA using both field strengths and 
found a 93% increase in CNR at 3 T compared to 1.5 T [45]. 
Sommer and coworkers directly compared 3 T to 1.5 T coro-
nary MRA to assess the accuracy of diagnosing coronary 
artery disease compared to the current “gold standard” of 
coronary angiography [46]. Using navigator-corrected, 3D 
turbo gradient-echo techniques at both field strengths, they 
found comparable image quality with a 30% increase in SNR 
and a 22% increase in CNR at 3 T. Overall, the diagnostic 
accuracy at both field strengths was equivalent, with 
sensitivity for the detection of CAD of 82% for both, and a 
specificity of 89% and 88% for 3 T and 1.5 T, respectively. 
However, newer techniques that were not employed at the 
time such as optimized T2 preparation pulses [47], parallel 
imaging [48], or advanced shimming algorithms [17] will 
likely contribute to superior results of coronary MRA at 
higher field strengths.  
  The use of CT to perform coronary angiography for the 
diagnosis of CAD has been progressing rapidly. A recently 
performed multi-center trial using multi-detector 64-Row CT 
reported a sensitivity of 85% and a specificity of 90% in 
detecting coronary stenoses > 50% on x-ray coronary 
angiography [49]. Heavily calcified vessels still present a 
hurdle to overcome for CT angiography, as the lumen cannot 
be visualized in a significant number of these segments. 
Overall, the diagnostic accuracy for the detection of 
significant CAD continues to favor the use of CTA over 
MRA. 
  A recent meta-analysis of 51 studies that each examined 
coronary CTA or MRA reported a significantly higher 
sensitivity and specificity for CTA (85%, 95% respectively) 
compared with that of coronary MRA (72%, 87% respec-
tively) for the detection of significant coronary stenoses [50].  
  Actually, there are no data available comparing state of 
the art coronary CT and coronary MRA at 3 T, e.g. favoring 
the use of a 32-channel receiver coil and a contrast-enhanced 
whole-heart approach [51]. 
CORONARY VESSEL WALL IMAGING 
  Coronary vessel wall imaging using CMR permits the 
non-invasive quantification for “Glagov-type” outward 
arterial remodeling and allows for the accurate measurement 
of vessel wall thickness [52]. Because thickening of the 
vessel wall precedes luminal narrowing, MRI has the ability 
to detect early coronary atherosclerosis (Fig. 4). In a study of 
patients with CAD, a free-breathing, navigator-gated tech-
nique for 3D coronary black blood imaging showed 
increased coronary vessel wall thickness in patients with 
mild CAD when compared to a healthy control population 
[53]. Preliminary studies of coronary vessel wall imaging at 
3 T are promising and show the potential to detect preclinical 
disease and monitor treatment effects over time [52, 54].
Fig. (4). (A) Black-blood image at 3 T of the proximal left anterior 
descending (LAD) (white arrow) in a CAD patient shows thickened 
coronary vessel wall (zoomed image – white arrow).  
SPECTROSCOPY 
  Cardiac MR spectroscopy (MRS) enables the non-
invasive assessment of high-energy phosphate metabolism 
and even flux through the creatine kinase reaction [55, 56] 
when applying phosphorus (
31P) MRS [57-61] or the 
myocardial triglyceride content with proton (
1H) MRS [62-
64]. Currently, however, cardiac MRS clinical use is limited, 
in large part to the inherent low concentration of the 
metabolites being studied which in turn restricts the 
achievable spatial resolution and often imposes long scan 
times [65]. Cardiac MRS at high field may profit from both 
increased SNR and spectral dispersion [66, 67] and will offer 
a powerful means to non-invasively probe critical metabolic 
processes in human heart disease. 
SUMMARY
  Cardiac MR imaging has evolved rapidly and is now 
accepted as a powerful diagnostic tool with significant 
clinical and research applications. Although technical 
challenges remain for cardiac imaging at higher field 
strengths such as bSSFP cine imaging, the majority of 
cardiac applications are feasible at 3 T with comparable or 
superior image quality to that of 1.5 T. Imaging at 3 T Cardiovascular Magnetic Resonance Imaging at 3 Tesla  Current Cardiology Reviews, 2009, Vol. 5, No. 3    241
particularly benefits protocols with sub-optimal SNR such as 
cardiac perfusion imaging, delayed enhancement imaging 
and myocardial tagging techniques. The integration of 
parallel imaging, motion compensation, and shimming 
algorithms at 3 T will contribute to further improvements of 
imaging quality and shorter scanning times.  
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